Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of MGTA-145 in Combination With Plerixafor for the Mobilization of Hematopoietic Stem Cells in Patients With Sickle Cell Disease

Next Previous
X
Search
Trial Profile

A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of MGTA-145 in Combination With Plerixafor for the Mobilization of Hematopoietic Stem Cells in Patients With Sickle Cell Disease

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MGTA 145 (Primary) ; Plerixafor (Primary)
  • Indications Sickle cell anaemia; Stem cell mobilisation
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Magenta Therapeutics

    • Most Recent Events

    • 07 Feb 2023 Status changed from recruiting to discontinued.
    • 13 Dec 2022 Trial design, presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2022 According to a Magenta Therapeutics media release, due to enrollment delays, data from the study is now expected to be shared H1 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top